Reciprocal Interactions between Breast Tumor and Its Adipose Microenvironment Based on a 3D Adipose Equivalent Model

Laetitia Delort1,2, Charlotte Lequeux3, Virginie Dubois1,2, Alice Dubouloz4, Hermine Billard1,2, Ali Mojallal4,5, Odile Damour4, Marie-Paule Vasson1,2,3, Florence Caldefie-Chézet1,2

1 Clermont Université, Université d’Auvergne, UFR Pharmacie, Laboratoire SVFp, Clermont-Ferrand, France, 2 INRA, UMR 1019, ECRIN, CRNH Auvergne, Clermont-Ferrand, France, 3 Centre Jean Perrin, Unité de Nutrition, Clermont-Ferrand, France, 4 Banque de tissus et de cellules, Hôpital Edouard-Herriot, Lyon, France, 5 Service de chirurgie plastique, reconstructrice et esthétique, Hôpital Edouard-Herriot, Lyon, France

Abstract

Breast cancer has become the most common cancer among women in industrialized countries. Obesity is well established as a risk factor, in particular owing to the attendant secretion of the entities called adipokines; there is growing evidence for a role of cells and factors present in the mammary tumor microenvironment such as fibroblasts, preadipocytes, adipocytes and their secretions. To study how the microenvironment influences breast cancer growth, we developed a novel tridimensional adipose model epithelialized with normal human keratinocytes or with breast cancer cell lines. These mimicked a breast tumor in contact with an adipose microenvironment and allowed monitoring of the interactions between the cells. Leptin and adiponectin, two major adipokines, and their respective receptors, ObRt and AdipoR1, were expressed in the model, but not the second adiponectin receptor, AdipoR2. The differentiation of preadipocytes into adipocytes was greater when they were in contact with the breast cancer cell lines. The contact of breast cancer cell lines with the microenvironment completely modified their transcriptional programs by increasing the expression of genes involved in cell proliferation (cyclinD1, MAPK), angiogenesis (MMP9, VEGF) and hormonal pathways (ESR1, IL6). This tridimensional adipose model provides new insights into the interactions between breast cancer cells and their adipose microenvironment, and provides a tool to develop new drugs for the treatment of both cancer and obesity.

Introduction

Breast cancer is by far the most common cancer among women worldwide, with 1.38 million new cases diagnosed in 2008, causing 458,000 deaths. The incidence of this cancer varies geographically being low in developing regions (South America, Africa and Asia) and a high incidence in developed countries (US and Western Europe) [1].

Obesity is now recognized as a risk factor for breast cancer, particularly in postmenopausal women, and is correlated with poor prognosis, larger tumor size, a higher incidence of lymph node metastasis and a high tumor grade [2]. In 2005, the world overweight population was 937 million (23.2%), of whom 396 million were obese (9.8%). In many industrialized countries, over one fifth of the adult population is obese, and this proportion is also increasing in developing countries [3].

Understanding the role of adipose tissue in breast cancer growth is of major interest in obese patients. There are several possible explanations of the relationship between breast cancer and adiposity. First, the larger amount of adipose tissue in obese patients is associated with a higher conversion of androgens to estrogens by aromatase, and higher circulating levels of insulin and insulin-growth factor (IGF), which then enhance cell proliferation [4]. Second, adipose tissue can produce greater amounts of the entities called adipokines, whose concentrations are modulated by obesity. Some recent studies have shown that adipose tissue is not only fat storage tissue, but is also an endocrine organ. We have demonstrated that leptin and adiponectin, the two main adipokines studied, exert proliferative and antiproliferative activities respectively on breast cancer cells in vitro [5]. Leptin, whose serum concentration is increased in obesity and breast cancer [6], stimulates cell proliferation by up-regulating the expression of cdk2 and cyclinD1 [7]. Inversely, low levels of adiponectin are significantly associated with an increased risk of breast cancer [8,9]. However, in vitro assays have shown that adiponectin decreased the proliferation of breast cancer cell lines (MCF7, MDA-MB-231) and induced apoptosis and cell cycle arrest [10,11]. In addition, these two adipokines and their respective receptors (ObR, AdipoR1 and AdipoR2) are detected by immunohistochemistry in in situ carcinomas, invasive ductal carcinomas and healthy adjacent tissues [3].

New hypotheses concerning the role of the total local tumor microenvironment have recently emerged. Mammary epithelial
cells are surrounded by stromal cells, such as preadipocytes, adipocytes, fibroblasts, and endothelial and inflammatory cells, and there is increasing evidence that factors produced by this tumor microenvironment, including extracellular matrix components and direct cell-cell contact, impact on breast carcinogenesis [12]. For example, adipocytes may promote cancer progression [13], and endothelial cells may regulate cancer cell proliferation and invasiveness. A recent study showed that the secretions of “dysfunctional” endothelial cells could enhance hyperplasia, angiogenesis and inflammation [14]. Variations in fibroblast distribution can also influence local breast estrogen synthesis and thereby promote tumor growth [15].

The role of this microenvironment in the proliferation of healthy or malignant cells is still not clear but warrants investigation in the case of breast cancer. We devised a tridimensional (3D) model to study the interactions between the adipose tumor microenvironment and breast cancer cells. For this purpose, an innovative adipose 3D model epithelialized with normal human keratinocytes or with breast cancer cell lines was developed. The latter mimicked a breast tumor, allowing a direct contact with the adipose microenvironment. A comparison of these models showed interactions in both directions: breast cancer cells were able to act on adipocyte differentiation, and the adipose microenvironment strikingly modified breast cancer cell transcriptional programs involved in major biological pathways.

Materials and Methods

Cell cultures

Primary cultures of keratinocytes and fibroblasts were established from human skin obtained from patients undergoing surgery, in accordance to ethical and safety guidelines drawn up in French regulation n° DC-2008-162.

Fibroblasts were isolated from the foreskin of a child donor (age<10 years). They were grown in Dulbecco’s modified Eagle’s medium (DMEM with glutamax-1, Invitrogen, Cergy-Pontoise, France) supplemented with 10% calf serum (HyClone, Logan, Utah, USA), 20 μg/ml gentamicin (Pantapharm, Fougères, France), 100 UI/ml penicillin (Sarbach, Suresnes, France) and 1 μg/ml amphotericin B (Bristol Myers Squibb, Puteaux, France).

Keratinocytes were obtained from the foreskin of a child donor (age<10 years). They were grown in a 3:1 mixture of DMEM and HAM F12 (Invitrogen), supplemented with 10% calf serum (HyClone), 10 ng/ml epidermal growth factor (EGF) (Austral biologic, San Ramon, California, USA), 0.12 UI/ml insulin (Lilly, Saint-Cloud, France), 0.4 μg/ml hydrocortisone (Up John, Saint-Quentin-en-Yvelines, France), 5 μg/ml triiodo-l-thyronine (Sigma, Saint-Quentin-Fallavier, France), 24.3 μg/ml adenine (Sigma) and antibiotics as above. All the skin samples were obtained with informed consent of their donors.

Human Adipose derived Stem Cells (ASC) from adipose tissue were isolated from liposorption of donors undergoing optimized liposuction [16] using a 3 mm canula according to ethical and safety guidelines as approved by the local IRB and as described by Björntorp [17]. Briefly, adipose tissue was digested with collagenase (0.120 U/ml, Roche, Indianapolis, USA) at 37°C for 30 min and under constant shaking. Digestion was stopped by adding Dulbecco’s modified Eagle’s medium (DMEM with glutamax, Gibco (Invitrogen, Carlsbad, USA) containing 10% fetal calf serum (FCS, HyClone, Logan, USA). Floating adipocytes were discarded and cells from the stromal-vascular fraction (SVF) were pelleted, rinsed with media, centrifuged (300 g min⁻¹ for 5 min, 20°C) and incubated in an erythrocyte lysis buffer for 10 min at 37°C. This cell suspension was centrifuged (300 g.min⁻¹ for 5 min, 20°C) and cells were counted using trypan blue and seeded at a density of 8×10⁴ cells/cm².

The mammary cell lines MCF7, MDA-MB-231 and MCF10a were obtained from the American Type Culture Collection (ATCC). MCF7 cells, which possesses estrogen receptor α (ERα), were cultured in RPMI 1640 medium (Pan Biotech, France) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Abcys, France), 0.04 U/ml insulin, 50 μg/ml gentamicin and 2 mM t-glutamine (Pan Biotech, France) and incubated at 37°C in a humidified atmosphere containing 5% CO₂. MDA-MB-231 cells, which are non-estrogen dependent cells and more invasive than MCF7, were grown in L15 Leibovitz (Pan Biotech, France) supplemented with 13% FBS, 50 μg/ml gentamicin and 2 mM t-glutamine and incubated at 37°C in a humidified atmosphere. MCF10a cells were cultured in DMEM/F-12 (Pan Biotech, France) supplemented with 10% horse serum (Pan Biotech, France), 20 ng/ml epidermal growth factor (EGF), 0.25 U/ml insulin, 0.5 μg/ml hydrocortisone (Sigma, Saint-Quentin-Fallavier, France), 100 ng/ml cholera toxin (Sigma, Saint-Quentin-Fallavier, France) and 50 μg/ml gentamicin in a 5% CO₂-humidified incubator at 37°C.

3D Culture

We used a 3D model of skin equivalent [18,19] (Patent PCT/FR/8800303, 1989) replacing the skin equivalent by an adipose skin equivalent in which breast cancer cell lines were in contact with different cell types such as fibroblasts, preadipocytes and adipocytes (Figure 1). This 3D structure mimicked a breast tumor surrounded by a microenvironment, with breast cell lines being in contact with fibroblasts, preadipocytes and mature adipocytes, and with all their secretions.

Fibroblasts (125,000 cells/cm²) and preadipocytes (125,000 cells/cm²) were seeded on top of the collagen-glycosaminoglycan-chitosan porous scaffold (dermal substrate) and cultured in DMEM/HAM F-12 (1:1) supplemented with 10% FBS, basicFGF (10 ng/mL), vitamin C and streptomycin (50 μg/mL), which was replenished every 2 days. After 3 weeks of culture, a fatty equivalent dermis was obtained and four different epithelial cell lines (one million) were seeded on the surface: keratinocytes (skin equivalent control), MCF10a, MCF7, and MDA-MB-231. Three independent specimens of each studied mammary cell line were used. At this step, the medium is a mixture between keratinocyte medium [20] and an optimized adipocyte differentiation medium [19]. Briefly it contains DMEM/HAM F12 (1:1) supplemented with 10% FBS, hydrocortisone, insulin, adenine, EGF, T3, vitamin C, dexamethazon, roziglitazone, IBMX (only the first three days), streptomycin and fungizon [19]. The medium was replenished every 2 days. After 1 week of culture, cells were grown at the air-liquid interface for 2 weeks to obtain the reconstructed fatty skin equivalent, i.e. 3D adipose skin equivalent.

Histological analysis

3D adipose skin equivalent was fixed in 10% buffered formalin and embedded in paraffin. Tissue sections 5 μm thick were stained with hematoxylin phloxin safran (HPS) to visualize nucleus, cytoplasm and ECM formation.

Oil Red O staining for evaluation of adipose differentiation

All the 3D adipose skin equivalents were fixed in O.C.T compound (TISSUE-TECK, Sakura, Netherlands) and frozen at −20°C. They were then cut into 5 μm-thick sections, stained with
Oil Red O (5 mg/ml, Sigma) and counterstained with Harris hematoxylin (Sigma).

Immunohistochemistry

3D adipose skin equivalent was fixed with formol and embedded in paraffin wax. Sections 0.5 µm thick were cut. The procedure was as described previously [21,22]. Briefly, sections were deparaffinized and rehydrated in graded alcohol and distilled water. Slides were pretreated by boiling in citrate buffer for 40 minutes at pH = 6. The avidin/biotin kit (Vector Laboratories, Burlingame, USA) was used to block non-specific binding sites. Leptin, adiponectin, AdipoR1, AdipoR2, and Ob-Rt protein expression was investigated by immunohistochemical staining using affinity-purified polyclonal biotinylated antibodies raised against leptin, Ob-Rt (corresponding to the extracellular domain recognizing all six forms of Ob-R), adiponectin (R&D Systems, France), AdipoR1, AdipoR2 (Phoenix Pharmaceuticals, France) (1 µg/mL) diluted in PBS-SAB 5% overnight at 4°C in a humidified chamber.

Antigen staining was performed using ABC peroxidase-conjugated streptavidin kit for 30 min and the specimens treated with DAB substrate for 10 minutes (Vector Laboratories, Burlingame, USA). Sections were then contrasted using hematoxylin, dehydrated and mounted using the Vectastain mounting medium.

Molecular analysis

Epithelial cells were separated from the rest of the skin by treatment with thermolysin and immediately frozen on liquid nitrogen. Total RNA was extracted by grinding in nitrogen and with Trizol according to the manufacturer’s recommendations (Invitrogen). The quantity and quality of RNA was assessed by 260/280 ratio using a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific). cDNA was obtained with HighCap cDNA RT Kit RNAse inhib (Applied Biosystems).

Relative expression of 32 genes of interest was assessed by Taqman Express plates on ABI PRISM 7900 HT (Applied Biosystems). Among the selected genes (Table 1), we determined the expression of genes coding for the two major adipokines (leptin and adiponectin) and their receptors (ObR, AdipoR1 and AdipoR2), genes involved in hormonal pathway (estrogen receptors, progesterone receptor, aromatase, insulin, IGF1), and genes

Figure 1. Development of the adipose skin equivalent. 1. Fibroblasts and preadipocytes were seeded on a dermal substrate. 2. After 3 weeks of culture, a fatty equivalent dermis was obtained and keratinocytes (control) or mammary cancer cells (MCF7, MDA-MB-231) or non-cancerous mammary cells (MCF10a) were then seeded on the dermis. 3. After one week of culture, these cells were grown at the air-liquid interface (2 weeks) to obtain the reconstructed fatty skin equivalent. 4. At the end of the experimentation, epithelial cells (n = 3) were separated from the dermis with a thermolysin treatment to extract RNA. The expression of 32 key genes was investigated by qRT-PCR and compared with the expression of cells cultured in normal conditions.

doi:10.1371/journal.pone.0066284.g001
coding for cytokines (IL6, TNF). We also determined the expression of genes involved in proliferation (AKT, MAPK1, cyclin D1), in apoptosis (Bax, Bcl2), in angiogenesis (MMP2, MMP9, VEGF), the expression of transcription factors (PPARα, PPARγ, STAT3), tumor suppressor genes (BRCA1, TP53, e-cadherin) and oncogene (MYC).

The PCRs were performed in 96-well plates in a total volume of 20 μL and 30 ng of cDNA. The program was as follows: two initial steps at 50°C for 2 min and 95°C for 10 min, and then 40 cycles of 95°C for 15 s and 60°C for 60 s. Relative amount was calculated from the threshold cycles with the instrument’s software (SDS 2.0) according to the manufacturer’s instructions. Genes were considered significantly expressed and their transcript measurable if their corresponding Ct value was less than or equal to 35. The expression levels of the target genes in the reconstructed skin fatty equivalent were compared with the expression of the same cell lines cultured under classic conditions, i.e. in their respective culture medium in flasks. The comparative cycle threshold (CT) method \(2^{-\Delta\Delta CT}\) was used to calculate the relative gene expression of a given sample in 3D skin equivalent, normalized within the sample to an endogenous reference gene (GAPDH), and relative to the expression of the same gene in another sample (cell cultured alone): \(2^{-\Delta\Delta CT}\) method with \(\Delta\Delta CT = \Delta CT (3D \text{ skin equivalent}) - \Delta CT (\text{cell cultured alone})\) and \(\Delta CT = \text{CT(target gene)} - \text{CT(reference gene)}\). Student’s t test was used for comparisons of gene expression levels in cells cultured in 3D and in cells cultured alone.

### Table 1. List of the selected genes.

| Gene symbol | Gene name | Assay reference |
|-------------|-----------|-----------------|
| 18S         | Eukaryotic 18S rRNA | 18S-Hs99999901_s1 |
| TP53        | tumor protein p53 | TP53-Hs01034249_m1 |
| BAX         | BCL2-associated X protein | BAX-Hs00180269_m1 |
| BCL2        | B-cell CLL/lymphoma 2 | BCL2-Hs99999018_m1 |
| CCND1       | cyclin D1 | CCND1-Hs99999004_m1 |
| MYC         | v-myc myelocytomatosis viral oncogene homolog | MYC-Hs00905030_m1 |
| IGF1        | insulin-like growth factor 1 | IGF1-Hs00153126_m1 |
| IGF1R       | insulin-like growth factor 1 receptor | IGF1R-Hs99999020_m1 |
| LEPR        | leptin receptor | LEPR-Hs00174492_m1 |
| ADIPOR1     | adiponectin receptor 1 | ADIPOR1-Hs01114951_m1 |
| ADIPOR2     | adiponectin receptor 2 | ADIPOR2-Hs000226105_m1 |
| ADIPOQ      | adiponectin | ADIPOQ-Hs00605917_m1 |
| LEP         | leptin | LEP-Hs00174877_m1 |
| INS         | insulin | INS-Hs00355773_m1 |
| INSR        | insulin receptor | INSR-Hs00961560_m1 |
| ESR1        | estrogen receptor 1 | ESR1-Hs01046812_m1 |
| ESR2        | estrogen receptor 2 (ER beta) | ESR2-Hs01100356_m1 |
| PGR         | progesterone receptor | PGR-Hs01556707_m1 |
| CYP19A1     | cytochrome P450, family 19, subfamily A, polypeptide 1 | CYP19A1-Hs00240671_m1 |
| VEGFA       | vascular endothelial growth factor A | VEGFA-Hs00173626_m1 |
| CDH1        | cadherin 1 | CDH1-Hs00170423_m1 |
| MMP2        | matrix metallopeptidase 2 | MMP2-Hs00234422_m1 |
| MMP9        | matrix metallopeptidase 9 | MMP9-Hs00597562_m1 |
| STAT3       | signal transducer and activator of transcription 3 | STAT3-Hs01047580_m1 |
| AKT1        | v-akt murine thymoma viral oncogene homolog 1 | AKT1-Hs00902053_m1 |
| MAPK1       | mitogen-activated protein kinase 1 | MAPK1-Hs01046830_m1 |
| TNF         | tumor necrosis factor | TNF-Hs00174128_m1 |
| IL6         | interleukin 6 | IL6-Hs00174131_m1 |
| PPARA       | peroxisome proliferator-activated receptor alpha | PPARA-Hs00947539_m1 |
| PPARG       | peroxisome proliferator-activated receptor gamma | PPARG-Hs01115513_m1 |
| BRCA1       | breast cancer 1, early onset | BRCA1-Hs01556194_m1 |
| GAPDH       | glyceraldehyde-3-phosphate dehydrogenase | GAPDH-Hs9999905_m1 |

*doi:10.1371/journal.pone.0066284.t001*
Results

Reconstructed three-dimensional (3D) adipose equivalent-Differentiation of preadipocytes

The experiment was validated with the results of culture control. Indeed, the 3D adipose model obtained with normal human keratinocytes (NHK) exhibited a balanced, pluristratified, and differentiated epidermis, close to human normal skin (Figure 2).

HPS staining showed that fibroblasts and preadipocytes colonized the dermal substrate. The negative Oil Red O staining specific to mature adipocytes showed that no differentiation of preadipocytes into mature adipocytes occurred.

In contrast to the NHK model, the differentiation of preadipocyte to mature adipocytes was observed in our 3D model with breast epithelial cells. In addition, differences were observed according to the cell line. With cystic mammary cells (MCF10a...
cell line), cysts were present in the epithelium and with cancerous MCF7 and MDA-MB-231 cell lines, the epithelium appeared pluristratified but non-differentiated and completely disorganized. Deeper in adipose connective tissue, preadipocyte differentiation into mature adipocytes was greater with these two cancerous cell lines. These results suggest that preadipocyte differentiation into mature adipocytes was only possible in the presence of breast cells in their microenvironment with a greatest effect occurring with breast cancer cells. They also suggest that interactions take place between adipose and cancerous cells as a result of the secretion of biomolecules through mechanisms not yet fully understood.

Breast cancer cells expressed adipokines and their receptors except for AdipoR2

The two major adipokines, leptin and adiponectin, were strongly expressed in all three models whatever the mammary epithelial cells used, cancerous MCF7, MDA-MD-231 and non-cancerous mammary cells MCF10a (Figure 3), but not in the model epithelialized with NHK. Their respective receptors, ObRt and AdipoR1 were expressed to a lesser extent. Unexpectedly, AdipoR2 was not expressed.
Adipose microenvironment modified the expression of genes involved in major biological pathways

Quantitative real-time PCR was used to assess the expression of 32 genes coding for adipokines and their receptors, for proteins involved in hormonal pathways, and in major biological pathways such as proliferation and angiogenesis, and to compare breast epithelial cells cultured alone in monolayered culture and cells in 3D adipose connective tissue model. The presence of fibroblasts and adipose cells (preadipocytes and mature adipocytes) and their secretions strikingly modified gene expression in breast cells.

The analysis of gene expression was made by principal component analysis (PCA) (Figure 4). The two first principal components account for 63% of the total variance. On the first principal component, a clear discrimination can be seen between cells cultured in the adipose skin equivalent model and those cultured in normal conditions. The second principal component discriminated the three studied cell lines (MCF7, MDA-MB-231 and MCF10a) cultured in control conditions, except for one assay of MDA-MB-231 cells cultured in control condition.

Figure 4. Principal component analysis (PCA) carried out to explore the differences among samples and relationships among genes. The expression of genes by mammary cell lines (MCF7, MDA-MB-231) cultured in control conditions (MCF7_Ctrl, MDA_Ctrl, MCF10a_Ctrl) or cultured in the adipose skin equivalent model (MCF7_3D, MDA_3D, MCF10a_3D) was evaluated using unit variance scaling on gene expression data. On the first principal component, a clear discrimination can be noted between cells cultured in the adipose skin equivalent model versus cells cultured in normal conditions. The second principal component permitted to discriminate the three studied cell lines (MCF7, MDA-MB-231 and MCF10a) among the control group.

doi:10.1371/journal.pone.0066284.g004

Hierarchical cluster analysis (HCA) (Figure 5) allowed us to evaluate the low to high expression of each gene in each control and 3D assay. It discriminated cells cultured in control conditions and cells cultured in the 3D model, except for one assay of MDA-MB-231 cultured in control condition. This representation led to the formation of expression blocks, red and green, of which the former was more strongly expressed.

The relative gene expression of a given sample in the 3D skin equivalent model calculated with the $2^{-\Delta\Delta CT}$ method (Table 2), revealed significant modifications in genes coding for adipokines in
Discussion

To gain a fuller understanding of the role of the adipose microenvironment in breast cancer growth, we developed a novel model of reconstructed adipose connective tissue that could be epithelialized either with cutaneous NHK, to produce a skin equivalent, or with cystic or tumor breast epithelial cells, to allow interactions between these breast epithelial cells and different cell types (fibroblasts, adipose cells and their secretions). Three mammary cell lines were studied in our model: MCF10a cells derived from a fibrocytic disease, considered as non-tumorigenic, served as a breast cell control, and two cancer cell lines, MCF7, which possesses estrogen receptor α (ERα), and MDA-MB-231, estrogen-insensitive cells which are considered to be more invasive. We observed a stronger differentiation of adipocytes in contact with cancer cells, and marked modifications of mammary cell transcriptional programs, which suggests the existence of reciprocal interactions.

Breast tumors are surrounded by different cell types including endothelial cells, fibroblasts, preadipocytes and adipocytes, and each cell type has the ability to secrete biomolecules that can act on breast cancer cells. Adipose tissue is now considered as an endocrine organ, in addition to being a fat storage tissue. It secretes several entities called adipokines, the most widely studied of which are leptin and adiponectin, which are respectively increased and decreased in obese patients [24]. Leptin is produced by preadipocytes, adipocytes, mammary epithelial cells and other tissues [25]. Increased serum concentration of leptin is correlated with obesity, and a high level of leptin is associated with breast cancer risk [6]. This adipokine is known to exert its activity through its receptor ObR, and ObR mRNA and their protein expressions have been observed in breast cancer cell lines [7]. Adiponectin, considered as a protective factor because it decreases cancer risk [6]. This adipokine is known to exert its activity through its receptor ObR, and ObR mRNA and their protein expressions have been observed in breast cancer cell lines [7]. Adiponectin, considered as a protective factor because it decreases the proliferation of cancerous cells [7], is produced sparingly by cancerous mammary cells but abundantly by adipose cells. Also, lower serum adiponectin concentrations have been reported in obese patients and in menopausal women with breast cancer [26].

The high protein expression of leptin and its receptor and the surprising absence of AdipoR2 in the adipose skin equivalent seeded with normal human keratinocytes point to the possible role of an adipose microenvironment in increasing leptin proliferative activity and down-regulating the expression of adiponectin receptor. Immunohistochemical studies have shown that leptin, adiponectin and their receptors (Ob-R, AdipoR1 and AdipoR2) are detected in the cytoplasm of MCF-7 breast cancer cells [5]. The mRNA of the two adiponectin receptors were also found in MDA-MB-231 [27]. Immunoblotting of total protein lysates showed that the two major isoforms of Ob-R were expressed at similar levels in different cell lines including MCF-7 and MDA-MB-231 [28]. MCF10a cells expressed leptin [29]. These results are in agreement with studies conducted on human biopsies showing leptin and Ob-R protein expression in breast cancer cells and in benign breast lesions [30].

Cancer cells (MCF-7 and MDA-MB-231) expressed adipokines at the transcriptional level. Nevertheless, no significant increase in these expressions was observed in the presence of the adipose microenvironment. The transcriptional levels of adiponectin MCF10a cells were significantly higher in the 3D configuration, which could explain their benign character compared to invasive MCF-7 cells.

We suggest there is a cross-talk between cancerous and adipose cells that allows maximal differentiation of preadipocytes into mature adipocytes, irrespective of estrogen receptor status. The same process was reported by Wang et al., who observed that...
tumor invasive potential was only obtained when these cells were cultured in a medium conditioned by both murine adipose cells and human breast cancer cells [13]. Inversely, media conditioned by MCF7 and MDA-MB-231 induced a reversion of human and murine adipose cells, the main component of the breast stroma, to a fibroblastic phenotype via two soluble factors (TGF-β1 and TNF-α). Also, adipocytes cultured with this conditioned media presented a decreased lipid accumulation [31]. Thus tumor cells may be able to modulate their microenvironment to favor tumor progression.

Estrogens are key biological factors in promoting breast carcinogenesis in estrogen receptor tumors. Adipose tissue becomes the most abundant producer of estrogen after menopause, as a result of aromatization of androgens by the aromatase. Our model shows differences in the hormonal pathways modified by the tumor environment. By contrast, the differentiation of mature adipocytes was not affected by estrogen receptor status.

Table 2. Variation of gene expression in the different cell lines studied between.

|                          | MCF7 Expression ratio | MDA-MB-231 Expression ratio | MCF10A Expression ratio |
|--------------------------|-----------------------|----------------------------|-------------------------|
| Adipokines               |                       |                            |                         |
| LEP                      | -                     | 14.2                       | 10.3                    | 0.01                    |
| LEPR                     | -                     | 1.2                        | 0.82                    | -                       |
| Adiponectin              | -                     | 1.9                        | 0.19                    | 23.3                    | 0.01                   |
| ADIPOR1                  | 0.4                   | 0.52                       | 0.1                     | 0.37                    | 3.5                     | 0.74                   |
| ADIPOR2                  | 4.8                   | 0.06                       | 2.2                     | 0.34                    | 5.1                     | 0.02                   |
| Hormonal pathway, cytokines |                       |                            |                         |
| CYP19A1                  | 1.9                   | 0.01                       | 8.3                     | 0.09                    | -                       |
| ESR1                     | 16.1                  | 0.01                       | 281.6                   | 0.04                    | -                       |
| ESR2                     | 2.1                   | 0.03                       | 3.3                     | 0.11                    | 18.6                    | 0.01                   |
| PGR                      | 2.5                   | 0.01                       | 3.9                     | 0.33                    | 21.9                    | 0.01                   |
| IGF1                     | -                     | 2.0                        | 0.09                    | 9.2                     | 0.01                   |
| IGF1R                    | 2.7                   | 0.23                       | -                       |                         |                         |
| IL6                      | 44.4                  | 0.01                       | 10.3                    | 0.39                    | 2.2                     | 0.19                   |
| INS                      | -                     | -                          | -                       |                         |                         |
| INSR                     | 18.8                  | 0.01                       | 6.8                     | 0.01                    | 48.9                    | 0.01                   |
| TNF                      | 2.2                   | 0.25                       | -                       |                         |                         |
| Angiogenesis             |                       |                            |                         |
| MMP2                     | -                     | -                          | -                       |                         |                         |
| MMP9                     | 3.2                   | 0.05                       | 0.1                     | 0.07                    | -                       |
| VEGFA                    | 15.9                  | 0.02                       | 2.9                     | 0.19                    | 21.8                    | 0.01                   |
| Apoptosis                |                       |                            |                         |
| BAX                      | 3.5                   | 0.11                       | 0.8                     | 0.69                    | 1.7                     | 0.14                   |
| BCL2                     | 68.7                  | 0.01                       | 2.8                     | 0.01                    | 41.3                    | 0.01                   |
| Proliferation-survival    |                       |                            |                         |
| AKT1                     | 2.2                   | 0.32                       | 1.4                     | 0.15                    | -                       |
| MAPK1                    | 11.3                  | 0.03                       | 3.2                     | 0.32                    | 4.2                     | 0.03                   |
| CCND1                    | 9.1                   | 0.04                       | 1.7                     | 0.48                    | -                       |
| Transcription factors    |                       |                            |                         |
| PPARA                    | -                     | 2.5                        | 0.53                    | 3.6                     | 0.03                   |
| PPARG                    | 3.9                   | 0.08                       | 3.4                     | 0.39                    | 5.3                     | 0.02                   |
| STAT3                    | 11.4                  | 0.06                       | 2.6                     | 0.26                    | 5.2                     | 0.02                   |
| Tumor suppressor genes, oncogenes |             |                            |                         |
| BRCA1                    | 7.1                   | 0.02                       | 1.6                     | 0.63                    | 2.7                     | 0.13                   |
| TP53                     | 1.7                   | 0.48                       | 0.7                     | 0.17                    | 2.8                     | 0.06                   |
| CDH1                     | 13.4                  | 0.05                       | 23.2                    | 0.39                    | -                       |
| MYC                      | 7.0                   | 0.01                       | 2.6                     | 0.33                    | 1.2                     | 0.81                   |

*Average expression level in 3D skin equivalent calculated with the 2^ΔΔCt method.

P values were obtained using a two-tailed Student’s t test to identify genes whose average expression levels were statistically significantly different between 3D skin equivalent and cells cultured alone.

doi:10.1371/journal.pone.0066284.t002
We postulate that (i) fibroblasts in contact with breast cells have higher aromatase activity, thereby enhancing estrogen biosynthesis, which in turn favors the progression of breast cancer [13], and (ii) although aromatase expression in breast cancer cells was not increased in our model, other markers that are able to stimulate aromatase activity, such as IGF, TNFα, IGF-1, exhibited greater mRNA expression [32]. Hence, the secretion of fibroblasts and adipocytes could result in higher estrogen production and in turn could increase breast cancer proliferation by interacting with estrogen receptors on surrounding cancer cells in a paracrine manner.

Increased BMI in postmenopausal women is associated with hyperinsulinemia, insulin-resistant type 2 diabetes and metabolic syndrome, which in turn are associated with a small increase in hormonal breast cancer risk. These conditions lead to elevated glucose blood concentration, increased secretion of insulin and induction of ER+ breast cancer cell lines [33]. The increase of INSR expression in our model suggested that estrogen and insulin cooperate to promote cell-cycle progression [34]. Also, insulin and IGF1 are able to stimulate ER transcriptional activity in breast cancer cells, even in the absence of estrogen [35].

Molecular analysis demonstrated that the tumor microenvironment induced profound changes in breast cancer (MCF7, ER+ and non-cancerous (MCF10a) cell proliferation. In contrast, the invasive character of MDA-MB-231 cells did not seem to be influenced by the adipose microenvironment. These results are in agreement with our previous observations (unpublished data) and those of Baini [36] who reported that leptin had no impact on proliferation of these estrogen-receptor negative cells. In addition, MDA-MB-231 cells often exhibited high basal gene expressions, which could also explain why gene expression ratio was unchanged.

The up-regulation of VEGF and matrix metalloproteinase 9, which have the ability to degrade the extracellular matrix, led to an increased invasive potential in MCF7 cancer cells. Proliferation was also stimulated with an increased expression of MAPK1 and cyclinD1 in these cells. The increase in cyclin D1 expression could be explained by the production of biomolecules from the adipose microenvironment that could stimulate cyclin D1 such as leptin. Thus, invasive potential was notably increased in cells surrounded by adipose cells and their secretions, except for MDA-MB-231, which were initially the most invasive of the cells studied.

Conversely, an up-regulation of CDH1 and BRCA1 could lead to the suppression of cellular transformation. However, studies have shown the enhanced expression of E-cadherin can represent an early stage in ovarian cancer [37]. Genetic alterations were identified in tumor-associated stroma from several independent cases of mammary carcinomas, suggesting the role of these mutations in the formation of epithelial tumors [38].

Co-cultures of mammary cancer cells and mature adipocytes from rats showed that mature adipocytes unlike preadipocytes promoted the growth of ER-positive cancer cells, but no effect was observed on apoptosis. In addition, preadipocytes, but not mature adipocytes, promoted a higher expression of the E-cadherin, suggesting a protective role of this cell type by an increase in cell adhesion [39].

Our model show, for the first time, the existence of a cross-talk between human adipose microenvironment and breast cell lines: the adipose microenvironment seems to modify the expression profile of tumor cells and the tumor cells seem to influence the differentiation of mature adipocyte. Determining the specific role of adipokines in breast cancer cells is of major importance. The cancer microenvironment, including adipocytes and fibroblasts, must be considered globally to understand breast cancerogenesis, particularly in obese patients in whom the expression of adipokines and estrogen is modified.

Acknowledgments

The authors thank Prof. Yves-Jean Bignon and Dominique Bernard-Gallon from the Laboratoire d’Oncologie Moleculaire (Centre-Jean-Perrin, Clermont-Ferrand) for the use of the ABI Prism® 7900HT Sequence Detection System (TaqMan, Applied Biosystems).

Author Contributions

Conceived and designed the experiments: LD CL AM OD MPV FCC. Performed the experiments: LD CL VD AD HB. Analyzed the data: LD CL VD HB. Contributed reagents/materials/analysis tools: LD CL VD HB. Wrote the paper: LD CL OD FCC.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–917.
2. Calle EE, Thun MJ (2004) Obesity and cancer. Oncogene 23: 6365–78.
3. Renehan AG, Soerjomataram I, Leitzmann MF (2010) Interpreting the worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–917.
4. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, et al. (2004) Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med (Berl) 82: 677–86.
5. Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, Mihailly F, Buechler C, et al. (2009) Determination of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 16: 1197–210.
6. Maccio A, Madeddu C, Gramignano G, Malas C, Floris C, et al. (2010) Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med (Berl) 82: 677–86.
7. Jarde T, Perrin S, Vasson MP, Caldefie-Chezet F (2011) Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 47: 35–43.
8. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, et al. (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89: 1102–7.
9. Takahata G, Miyoshi Y, Irahara N, Taniguchi T, Tamaki Y, et al. (2007) Demonstration of adiponectin receptors 1 and 2 mRNA expression in human breast cancer cells. Cancer Lett 250: 229–36.
10. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, et al. (2005) Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28: 1263–9.
11. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, et al. (2006) Adiponectin modulates the glucose synthase kinase 3beta/catenin signaling pathway and attenuates mammary tumorogenesis of MDA-MB-231 cells in nude mice. Cancer Res 66: 11462–70.
12. Iyengar P, Combis TP, Shah SJ, Gnouen-Evans V, Pollard JW, et al. (2003) Adipocyte-secreted factors synergistically promote mammary tumorogenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 22: 6408–23.
13. Dirat B, Bochet L, Dabek M, Daviaud D, Davuiller S, et al. (2011) Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 71: 2453–63.
14. Frances JW, Baker AB, Chitalia VC, Edelman ER (2011) Stromal endothelial cells directly influence cancer progression. Sci Transl Med 3: 66ra5–3.
15. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER (1993) A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77: 1622–8.
16. Mogjali A, Auxenfans C, Lequeux C, Braye F, Damour O (2006) Influence of negative pressure when harvesting adipose tissue on cell yield of the stromal-vascular fraction. Biomed Mater Eng 18: 193–7.
17. Bjorntorp P, Karlsson M, Pettersson P (1982) Expansion of adipose tissue storage capacity at different ages in rats. Metabolism 31: 366–73.
18. La Vecchia C (2006) Oral contraceptives and ovarian cancer: an update, 1998–2004. Eur J Cancer Prev 15: 117–24.
20. Black AF, Bouez C, Perrier E, Schlotmann K, Chapois F, et al. (2005). Optimization and characterization of an engineered human skin equivalent. Tissue Eng 11: 723–33.

21. Dubois V, Delott L, Michellany F, Jarde T, Billard H, et al. (2010). Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? Anticancer Res 30: 2019–25.

22. Jarde T, Caldefie-Chezet F, Danez M, Michellany F, Perriere D, et al. (2008). Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology 53: 404–7.

23. Caraux G, Pinloche S (2005). PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 21: 1280–1.

24. Vona-Davis L, Howard-McNatt M, Rose DP (2007). Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 8: 393–408.

25. Cleary MP, Ray A, Rogozina OP, Dogan S, Grossmann ME (2009). Targeting the adiponectin/leptin ratio for postmenopausal breast cancer prevention. Front Biosci (Schol Ed) 1: 329–57.

26. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, et al. (2007). Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 92: 1510–6.

27. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, et al. (2008). Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 20: 971–7.

28. Ozbay T, Nahta R (2008). A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells. Mol Cancer Res 6: 1052–8.

29. O'Brien SN, Welter BH, Price TM (1999). Presence of leptin in breast cell lines and breast tumors. Biochem Biophys Res Commun 259: 695–8.

30. Caldefie-Chezet F, Danez M, de Latour M, Konika G, Michellany F, et al. (2005). Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun 354: 737–41.

31. Guerrero J, Tebar N, Caceres M, Espinoza L, Escobar P, et al. (2010). Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF-beta1 and TNF-alpha. Breast Cancer Res Treat 119: 497–508.

32. Paroutih A, Newman SP, Reed MJ (2002). The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 4: 65–9.

33. Golden J, Leake R, Kerr DJ (1992). The response of breast cancer cells to steroid and peptide growth factors. Anticancer Res 12: 1683–8.

34. Masoum A, Lai A, Carroll JS, Seegio CM, Mitchell CJ, et al. (2005). Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 229: 161–73.

35. Yoo D, Lee AV (2000). Cross-talk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 5: 107–15.

36. Onwugbufor K, Pan J, Groove BD, Peterson T, Fisher J, et al. (1999). Estrogen induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci U S A 96: 6249–54.

37. Moinfar F, Man YG, Atuchovsky IA, Grassauer GL, Ratschek M, et al. (2000). Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 60: 2562–6.

38. Manabe Y, Todaka S, Miyazaki K, Sugihara H (2003). Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol 201: 221–8.